Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-01-14

Clinical Trial Update: Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating nilotinib treatment-free remission in chronic myeloid leukemia patients has completed, with results posted January 14, 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myelogenous Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2021-01-14